VBI Vaccines Profile

USD 0.05  1.71%

VBI Vaccines exotic insider transaction detected

VBI Vaccines insider trading alert for general transaction of restricted stock units (rsus) by Steven Gillis, the corporate stakeholder, on July 14, 2018. This event was filed by Vbi Vaccines Inc with SEC on 2017-03-31. Initial filing of beneficial ownership - SEC Form 3. Steven Gillis is currently serves as independent chairman of the board of VBI Vaccines [view details]   

VBI Vaccines Summary

VBI Vaccines (VBIV) is traded on Nasdaq Capital Markets in USA. It is located in 222 Third Street and employs 98 people. The company currently falls under 'Small-Cap' category with current market capitalization of 184.94 M. VBI Vaccines conducts business under Healthcare sector and is part of Biotechnology industry. This company has 64.22 M outstanding shares of which 976.19 K shares are at this time shorted by private and institutional investors with about 3.2 trading days to cover. VBI Vaccines Inc. currently holds about 58.09 M in cash with (31.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.9.
Check VBI Vaccines Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 2.88HorizonTargetOdds Above 2.88
37.67%30 days 2.88 62.14%
Based on normal probability distribution, the odds of VBI Vaccines to move above current price in 30 days from now is about 62.14% (This VBI Vaccines probability density function shows the probability of VBI Vaccines Stock to fall within a particular range of prices over 30 days) .

Top Holders

VBI Vaccines Risk Profiles

Key Fundamentals

VBI Vaccines Against Markets

Current Ratings

VBI Vaccines 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
Equity ratings for VBI Vaccines are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines operates under Biotechnology classification in USA and traded on Nasdaq Capital Markets. It employs 98 people. more
NameVBI Vaccines
CEO, DirectorJeff BaxterView All
Analyst Consensus
Macroaxis Advice
InstrumentUSA Stock View All
Business Address222 Third Street
ExchangeNasdaq Capital Markets
Phone617 830 3031
CurrencyUSD - US Dollar

VBI Vaccines Corporate Directors

Ran Nussbaum Director
Tomer Kariv Director
Adam Logal Director
Also please take a look at World Market Map. Please also try Financial Widgets module to easily integrated macroaxis content with over 30 different plug-and-play financial widgets.